Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
On Demand
Back
Favorite
Facebook
Tweet
Print
Didem Torumkuney, PhD
Scientific Director
GSK, United Kingdom
Disclosure(s): GSK: Employee, Stocks/Bonds (Public Company)
Poster(s):
(P-1059)
In vitro
Activity of Gepotidacin against
Klebsiella pneumoniae
, Including Molecularly Characterized ESBL and Carbapenemase positive Subsets Causing Urinary Tract Infections in the United States (2019-2022)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1060)
In vitro
Activity of Gepotidacin Tested Against Molecularly Characterized
Escherichia coli
Isolates Responsible for Urinary Tract Infections in the US (2019-2022)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1061)
In vitro
Activity of Gepotidacin against
Klebsiella pneumoniae
, Including Molecularly Characterized Fluoroquinolone not Susceptible Subsets Causing Urinary Tract Infections in the United States (2019-2022)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1062)
In vitro
Activity of Gepotidacin and Comparator Agents against a Collection of
K. pneumoniae
Urine Isolates from the United States During 2019-2022
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1101) A Comparative Analysis of Resistance Rates Among
Escherichia coli
and
Klebsiella pneumoniae
Isolates Collected from the Gepotidacin Uropathogen Global Surveillance Studies and Phase 3 Uncomplicated Urinary Tract Infection Clinical Studies
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1511)
In Vitro
Activity of Gepotidacin Against Molecularly Characterized
Neisseria gonorrhoeae
Isolates Exhibiting Reduced Susceptibility to Antibacterial Agents, 2018-2021
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
